 "reddy, dr reddy's")
Dr Reddy’s Laboratories hit 52-week low of Rs 2,554 on BSE in intra-day trade ahead of its January-March quarter (Q4FY17) results today.
Since February 3, post October-December (Q3FY17) results, the stock of drug Company has underperformed the market by falling 19% as compared to 7% rise in the S&P BSE Sensex.
Dr Reddy's had reported 19% year on year (YoY) drop in net profit at Rs 470 crore in Q3FY17 against Rs 579 crore during the corresponding quarter in FY16. Revenues for Q3FY17 dropped 7% to Rs 3,707 crore as against Rs 3,968 crore in Q3FY16.
Edelweiss
Since February 3, post October-December (Q3FY17) results, the stock of drug Company has underperformed the market by falling 19% as compared to 7% rise in the S&P BSE Sensex.
Dr Reddy's had reported 19% year on year (YoY) drop in net profit at Rs 470 crore in Q3FY17 against Rs 579 crore during the corresponding quarter in FY16. Revenues for Q3FY17 dropped 7% to Rs 3,707 crore as against Rs 3,968 crore in Q3FY16.
Edelweiss
